Dr. Mezzanotte is a first-time Board nominee. He is responsible for developing and executing CSL’s Research & Development strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success.
In 2017, he joined the company as Head of Clinical Development, responsible for clinical science, statistics and clinical operations across CSL Behring's portfolio. Most recently he served as Senior Vice President and Head of Development, where he oversaw regulatory, project management, clinical science & operations, plasma, recombinant protein and gene therapy pharmaceutical development activities worldwide.
Prior to CSL, Dr. Mezzanotte was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas.
He holds an undergraduate degree from Villanova University, obtained his M.D. at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University, and is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine.